In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.

Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths / Strollo, R.; Maddaloni, E.; Dauriz, M.; Pedone, C.; Buzzetti, R.; Pozzilli, P.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 171:(2021). [10.1016/j.diabres.2020.108444]

Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths

Maddaloni E.;Buzzetti R.;
2021

Abstract

In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.
File allegati a questo prodotto
File Dimensione Formato  
Strollo_DPP4-inhibitors_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 493.99 kB
Formato Adobe PDF
493.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1521685
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact